Zenas Submits BLA To FDA For Obexelimab In IgG4-RD

India, May 28 -- Zenas BioPharma, Inc. (ZBIO), a clinical-stage biopharmaceutical company, reported on Thursday its submission of Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Obexelimab in treating patients with Immunoglobulin G4-Related disease or IgG4-RD. Obexelimab is an investigational, bifunctional monoclonal antibody designed to inhibit B-cell functions by binding to CD19, a protein found on the surface of B cells and FcgRIIb, a receptor found on B cells and other immune cells. Immunoglobulin G4-Related disease is a chronic fibro-inflammatory disease which affects multiple organ systems. If untreated, it often results in irreversible tissue damage and organ failure.

The company has submitted ...